WO2003082256A2 - Traitement des dysfonctionnements sexuels a l'aide d'un antagoniste des recepteurs aux cannabinoides cb1 - Google Patents
Traitement des dysfonctionnements sexuels a l'aide d'un antagoniste des recepteurs aux cannabinoides cb1 Download PDFInfo
- Publication number
- WO2003082256A2 WO2003082256A2 PCT/FR2003/000964 FR0300964W WO03082256A2 WO 2003082256 A2 WO2003082256 A2 WO 2003082256A2 FR 0300964 W FR0300964 W FR 0300964W WO 03082256 A2 WO03082256 A2 WO 03082256A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- receptor antagonist
- sexual
- useful
- cannabinoid receptor
- performances
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Definitions
- the present invention relates to a new use of a cannabinoid receptor antagonist CBi or OB ⁇ receptors. More particularly, the invention relates to the use of a CBl receptor antagonist for the preparation of medicaments useful for the treatment of dysfunctions of sexual behavior and / or the improvement of sexual performance in mammals, in particular in 'man.
- patent application WO 01/70700 discloses phenol derivatives.
- European patent EP-B-576,357, patent applications WO 01/29007 and WO 01/70700 describe pyrazole derivatives which are CBi receptor antagonists; more particularly, N-piperidino-5- (4-chlorophenyl) -1- (2,4-dichlorophenyl) -4-methylpyrazole-3-carboxamide, the international common name of which is rimonabant, its pharmaceutically acceptable salts and their solvates, are described in European patent EP-B-656 354 and by M. Rinaldi-Carmona et al. (FEBS Lett., 1994, 350, 240-244), as CBi receptor antagonists.
- Another cannabinoid CBi receptor antagonist derived from pyrazole is N-piperidino-5- (4-bromophenyl) -l- (2,4-dichlorophenyl) -4-ethylpyrazole-3-carboxamide and its pharmaceutically acceptable salts and their solvates which are described in patent application EP-A-1 150 961.
- rimonabant and its salts which are CB ⁇ cannabinoid behavior receptor antagonists can be used for the treatment of appetite disorders and in the treatment of disorders related to the use of psychotropic substances.
- international application WO99 / 00119 discloses the use of cannabinoid receptor antagonists CBi to treat appetite disorders, for example regulating cravings, in particular for the consumption of sugars, carbohydrates, alcohol or drugs and more generally appetizing ingredients. It has now been found that CBi cannabinoid receptor antagonists are useful in the treatment of dysfunctions in sexual behavior and / or for the improvement of sexual performance, in mammals, in particular in humans.
- the present invention relates to the use of a CB cannabinoid receptor antagonist for the preparation of medicaments useful in the treatment of dysfunctions of sexual behavior and for the improvement of sexual performance.
- Compounds that are antagonistic to the CB ⁇ cannabinoid receptors which are particularly useful for the use according to the invention are the pyrazole derivatives described in the patents and patent applications cited above and very particularly rimonabant and N-piperidino-5- ( 4-bromophenyl) -1- (2,4-dichlorophenyl) -4-ethylpyrazole-3-carboxamide as well as their pharmaceutically acceptable salts and their solvates.
- the cannabinoid receptor antagonist CB ⁇ For its use as a medicament, the cannabinoid receptor antagonist CB ⁇ , one of its pharmaceutically acceptable salts or one of their solvates, must be formulated in pharmaceutical composition.
- compositions of the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, transdermal or local administration
- the active principle can be administered in particular in unit form, in mixture with conventional pharmaceutical carriers, to animals and human beings.
- Suitable administration forms include oral forms such as tablets, capsules, pills, powders, granules and oral solutions or suspensions, sublingual and oral administration forms, local administration forms , intracavernosa, transdermal, intramuscular, intravenous.
- the active principle or the active principles are generally formulated in dosage units.
- the dosage unit contains 0.5 to 300 mg, advantageously from 1 to 60 mg, preferably from 5 to 40 mg per dosage unit, for daily administrations, one or more times a day.
- the appropriate dosage for each patient is determined by the doctor according to the mode of administration, the age, the weight and the response of said patient.
- the cannabinoid receptor antagonist CB j is administered orally, in a single administration.
- Rimonabant administered at doses 1, 3 and 10 mg / kg orally, in the naive male rat caused a significant reduction in the mounting latencies and the induction latencies. These results show the stimulating effect of sexual performance in the male rat.
- EXAMPLE 1 capsule dosed with 5 mg of rimonabant.
- EXAMPLE 2 capsule dosed with 10 mg of rimonabant.
- EXAMPLE 4 tablet containing 10 mg of N-piperidino-5- (4-bromophenyl) -l- (2,4-dichlorophenyl) -4-ethylpyrazole-3-carboxamide.
- Purified water Q.S. For a tablet finished at 300 mg EXAMPLE 5: tablet dosed with 30 mg of rimonabant.
- Purified water Q.S. For a tablet finished at 400 mg
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003244722A AU2003244722A1 (en) | 2002-03-28 | 2003-03-27 | Use of a cb1 cannabinoid receptor antagonist for producing medicaments which are useful for treating sexual behaviour problems and/or for improving sexual performances |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0203961A FR2837706A1 (fr) | 2002-03-28 | 2002-03-28 | Utilisation d'un antagoniste des recepteurs aux cannabinoides cb1 pour la preparation de medicaments utiles pour traiter les dysfonctionnements sexuels et/ou ameliorer les performances sexuelles |
FR02/03961 | 2002-03-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003082256A2 true WO2003082256A2 (fr) | 2003-10-09 |
WO2003082256A3 WO2003082256A3 (fr) | 2004-04-01 |
Family
ID=27839313
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2003/000964 WO2003082256A2 (fr) | 2002-03-28 | 2003-03-27 | Traitement des dysfonctionnements sexuels a l'aide d'un antagoniste des recepteurs aux cannabinoides cb1 |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2003244722A1 (fr) |
FR (1) | FR2837706A1 (fr) |
WO (1) | WO2003082256A2 (fr) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
US7271266B2 (en) | 2002-03-28 | 2007-09-18 | Merck & Co., Inc. | Substituted 2,3-diphenyl pyridines |
EP1886684A1 (fr) * | 2006-08-07 | 2008-02-13 | Ratiopharm GmbH | Composition pharmaceutique comprenant du rimonabant |
US7348456B2 (en) | 2002-12-19 | 2008-03-25 | Merck & Co., Inc. | Substituted amides |
US7423067B2 (en) | 2002-03-26 | 2008-09-09 | Merck & Co., Inc. | Diphenyl cyclopentyl amides as cannabinoid-1 receptor inverse agonists |
US7667053B2 (en) | 2002-04-12 | 2010-02-23 | Merck & Co., Inc. | Bicyclic amides |
EP2305220A2 (fr) | 2004-03-09 | 2011-04-06 | Institut National de la Santé et de la Recherche Médicale - Inserm | Utilisation d'antagonistes des récepteurs CB1 pour la fabrication d'un médicament destiné au traitement des maladies hépatiques |
US9238027B2 (en) | 2009-01-12 | 2016-01-19 | Fundacion Del Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion (Fuhnpaiin) | Use of CB1 antagonists and/or inverse agonists for the preparation of drugs that increase motor neuron excitability |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0656354A1 (fr) * | 1993-12-02 | 1995-06-07 | Sanofi | N-pipéridino-3-pyrazolecarboxamide substitué |
WO2000046209A1 (fr) * | 1999-02-01 | 2000-08-10 | Sanofi-Synthelabo | Derives d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant |
WO2001064633A1 (fr) * | 2000-03-03 | 2001-09-07 | Aventis Pharma S.A. | Compositions pharmaceutiques contenant des derives de 3-amino-azetidine, les nouveaux derives et leur preparation |
WO2002053140A2 (fr) * | 2001-01-02 | 2002-07-11 | Pharmacia & Upjohn Company | Nouvelles combinaisons medicamenteuses |
-
2002
- 2002-03-28 FR FR0203961A patent/FR2837706A1/fr active Pending
-
2003
- 2003-03-27 AU AU2003244722A patent/AU2003244722A1/en not_active Abandoned
- 2003-03-27 WO PCT/FR2003/000964 patent/WO2003082256A2/fr not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0656354A1 (fr) * | 1993-12-02 | 1995-06-07 | Sanofi | N-pipéridino-3-pyrazolecarboxamide substitué |
WO2000046209A1 (fr) * | 1999-02-01 | 2000-08-10 | Sanofi-Synthelabo | Derives d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant |
WO2001064633A1 (fr) * | 2000-03-03 | 2001-09-07 | Aventis Pharma S.A. | Compositions pharmaceutiques contenant des derives de 3-amino-azetidine, les nouveaux derives et leur preparation |
WO2002053140A2 (fr) * | 2001-01-02 | 2002-07-11 | Pharmacia & Upjohn Company | Nouvelles combinaisons medicamenteuses |
Non-Patent Citations (7)
Title |
---|
DALTERIO S ET AL: "Cannabinoids inhibit testosterone secretion by mouse testes in vitro." SCIENCE. UNITED STATES 24 JUN 1977, vol. 196, no. 4297, 24 juin 1977 (1977-06-24), pages 1472-1473, XP008012074 ISSN: 0036-8075 * |
FERRARI F ET AL: "INHIBITORY EFFECTS OF THE CANNABINOID AGAINST HU 210 ON RAT SEXUAL BEHAVIOUR" PHYSIOLOGY AND BEHAVIOR, ELSEVIER SCIENCE LTD., OXFORD, GB, vol. 69, no. 4/5, 1 juin 2000 (2000-06-01), pages 547-554, XP001128190 ISSN: 0031-9384 * |
MANI S K ET AL: "PROGESTERONE RECEPTOR AND DOPAMINE RECEPTORS ARE REQUIRED IN DELTA9-TETRAHYDROCANNABINOL MODULATION OF SEXUAL RECEPTIVITY IN FEMALE RATS" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 98, no. 3, 30 janvier 2001 (2001-01-30), pages 1249-1254, XP001128188 ISSN: 0027-8424 * |
OTTANI A ET AL: "NEUROLEPTIC-LIKE PROFILE OF THE CANNABINOID AGONIST, HU 210, ON RODENT BEHAVIOURAL MODELS" PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, OXFORD, GB, vol. 26, no. 1, 2002, pages 91-96, XP001133701 ISSN: 0278-5846 * |
SODERSTROM K ET AL: "BEHAVIORAL, PHARMACOLOGICAL, AND MOLECULAR CHARACTERIZATION OF AN AMPHIBIAN CANNABINOID RECEPTOR" JOURNAL OF NEUROCHEMISTRY, NEW YORK, NY, US, vol. 75, no. 1, 2000, pages 413-423, XP001128191 ISSN: 0022-3042 * |
STELLA N: "HOW MIGHT CANNABINOIDS INFLUENCE SEXUAL BEHAVIOR?" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 98, no. 3, 30 janvier 2001 (2001-01-30), pages 793-795, XP001128187 ISSN: 0027-8424 * |
WENGER T ET AL: "THE EFFECTS OF CANNABINOIDS ON THE REGULATION OF REPRODUCTION" LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB, vol. 65, no. 6/7, 1999, pages 695-701, XP001128193 ISSN: 0024-3205 * |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7423067B2 (en) | 2002-03-26 | 2008-09-09 | Merck & Co., Inc. | Diphenyl cyclopentyl amides as cannabinoid-1 receptor inverse agonists |
US7271266B2 (en) | 2002-03-28 | 2007-09-18 | Merck & Co., Inc. | Substituted 2,3-diphenyl pyridines |
US7667053B2 (en) | 2002-04-12 | 2010-02-23 | Merck & Co., Inc. | Bicyclic amides |
US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
US7576239B2 (en) | 2002-12-19 | 2009-08-18 | Merck & Co., Inc. | Substituted amides |
US7348456B2 (en) | 2002-12-19 | 2008-03-25 | Merck & Co., Inc. | Substituted amides |
US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
US7354929B2 (en) | 2003-04-23 | 2008-04-08 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
EP2305220A2 (fr) | 2004-03-09 | 2011-04-06 | Institut National de la Santé et de la Recherche Médicale - Inserm | Utilisation d'antagonistes des récepteurs CB1 pour la fabrication d'un médicament destiné au traitement des maladies hépatiques |
EP1886684A1 (fr) * | 2006-08-07 | 2008-02-13 | Ratiopharm GmbH | Composition pharmaceutique comprenant du rimonabant |
US9238027B2 (en) | 2009-01-12 | 2016-01-19 | Fundacion Del Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion (Fuhnpaiin) | Use of CB1 antagonists and/or inverse agonists for the preparation of drugs that increase motor neuron excitability |
US9592237B2 (en) | 2009-01-12 | 2017-03-14 | Fundacion Del Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion (Fuhnpaiin) | Use of CB1 antagonists and/or inverse agonists for the preparation of drugs that increase motor neuron excitability |
Also Published As
Publication number | Publication date |
---|---|
WO2003082256A3 (fr) | 2004-04-01 |
AU2003244722A1 (en) | 2003-10-13 |
FR2837706A1 (fr) | 2003-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1257275B1 (fr) | Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac | |
EP0969835B1 (fr) | Utilisation d' antagonistes des recepteurs aux cannabinoides centraux pour reguler l'appetence | |
EP1221952B1 (fr) | UTILISATION D'UN ANTAGONISTE DES RECEPTEURS AUX CANNABINOiDES CENTRAUX POUR LA PREPARATION DE MEDICAMENTS | |
BE1005086A5 (fr) | Compositions pour l'administration buccale. | |
WO2003082256A2 (fr) | Traitement des dysfonctionnements sexuels a l'aide d'un antagoniste des recepteurs aux cannabinoides cb1 | |
WO2001085092A2 (fr) | Antagoniste des recepteurs aux cannabinoides cb-1 antidiarrheique | |
WO1997021439A1 (fr) | Medicament destine au traitement des troubles obsessifs compulsifs, de l'apnee du sommeil, des dysfonctions sexuelles, de l'emese et du mal des transports | |
EP1441723B1 (fr) | Utilisation de l'irbesartan pour la prevention ou le traitement de l'hypertension pulmonaire | |
BE1009060A3 (fr) | Compositions pharmaceutiques et procede permettant leur preparation. | |
FR2633831A1 (fr) | Composition associant un antagoniste de 5ht3 a un inhibiteur de cyclo-oxygenase, son procede de fabrication et l'utilisation combinee d'un antagoniste de 5ht3 et d'un inhibiteur de cyclo-oxygenase en therapeutique | |
WO2000061125A2 (fr) | L'osanetant dans le traitement des troubles de l'humeur | |
CH678149A5 (fr) | ||
EP2146714B1 (fr) | Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson | |
LU85242A1 (fr) | Nouvelle association medicamenteuse | |
FR2882263A1 (fr) | Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement des maladies renales | |
EP2131842A2 (fr) | Utilisation d'un compose antagoniste des recepteurs nk-2 de la neurokinine a pour la preparation de medicaments utiles pour la prevention et le traitement des dysfonctions sexuelles | |
FR2882261A1 (fr) | Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2 | |
WO2000066117A1 (fr) | Utilisation du (2s)-1- [(2r,3s)-5- chloro-3- (2-chlorophenyl)-1- (3,4-dimethoxybenzenesulfonyl)- 3-hydroxy-2,3- dihydro-1h-indole-2-carbonyl] pyrrolidine- 2-carboxamide pour la preparation de medicaments utiles dans le traitement du phenomene de raynaud | |
FR2623713A1 (fr) | Composition pharmaceutique destinee au traitement de troubles gastro-intestinaux | |
FR2527077A1 (fr) | Nouveau medicament a base d'un anti-depresseur et d'un alcaloide ergopeptidique | |
FR2882264A1 (fr) | Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |